Acadia pharmaceuticals, inc. ACAD.US 總覽分析

美股醫療保健
(Powered by Quartr Logo)

ACAD 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面獲得最高評分,但股利評分未超過2分,若公司開始配息,可能會有更優異的投資結果

ACAD 近期報酬表現

0.74%

Acadia pharmaceuticals, inc.

-2.96%

同產業平均

-1.61%

S&P500

與 ACAD 同產業的標的表現

  • TEM Tempus ai inc
    價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分
    查看更多

ACAD 公司資訊

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

ACAD 股價